EMERYVILLE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. , (NTI(R)), a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates, today announced that Paul E. Freiman, President and Chief Executive Officer will participate in a Stroke Panel Discussion and also present at the BIO InvestorForum 2006 in San Francisco, California. The conference is being held October 17-19, 2006, at the Palace Hotel in San Francisco.
Mr. Freiman will participate in a Stroke Panel Discussion on Wednesday, October 18, at 9:30 a.m. in the Twin Peaks Room and he will present the NTI story at 12:20 pm in the Telegraph Room. Both events will be web cast and available on the NTI website (www.ntii.com) by going to the following link:
http://www.shareholder.com/ntii/medialist.cfm
The BIO InvestorForum 2006 highlights growth companies in the life science industry. Companies share their clinical strategy and insights into new development and opportunities in the industry to an audience of institutional investors, hedge funds, bankers and private equity investors.
About Neurobiological Technologies, Inc.
NTI is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The Company's strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia and we may seek partnerships with pharmaceutical and biotechnology companies to assist us.
Neurobiological Technologies, Inc.CONTACT: Paul E. Freiman, President and CEO of NeurobiologicalTechnologies, Inc., +1-510-595-6000; or Marlon Nurse, VP - InvestorRelations of Porter, LeVay & Rose, Inc., +1-212-564-4700, forNeurobiological Technologies, Inc.
Web site: http://www.ntii.com/
